Kyverna Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kyverna Therapeutics, Inc. (Nasdaq: KYTX) on June 30, 2025. The filing reports the appointment of a new Chief Financial Officer (CFO) and the transition of the former CFO to a strategic advisor role. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the leadership transition within the finance function:
- Appointment: Marc Grasso, MD, was appointed as Chief Financial Officer, effective June 30, 2025. He will serve as the principal financial and accounting officer.
- Departure: Ryan Jones ceased serving as CFO, principal financial officer, and principal accounting officer effective June 30, 2025.
- Transition: Mr. Jones will serve as a strategic advisor to Dr. Grasso from June 30, 2025, through August 8, 2025, to ensure a seamless transition.
Compensation, Outlook, and Risks
New CFO Compensation (Marc Grasso):
- Base Salary: $510,000 annualized.
- Sign-on Bonus: $250,000 total ($100,000 paid shortly after the effective date; $150,000 paid on January 1, 2026, contingent on continued employment or termination without Cause).
- Performance Bonus: Eligible for up to 40% of base salary (fixed at target for 2025).
- Equity: Option to purchase 450,000 shares of common stock, vesting over four years (25% at one-year anniversary, monthly thereafter).
- Severance: 12 months of base salary and COBRA reimbursement upon termination without Cause or resignation for Good Reason. Full acceleration of unvested equity occurs if separation happens within 12 months of a Change in Control.
Former CFO Transition Compensation (Ryan Jones):
- Advisor Period: Continues current salary and benefits through August 8, 2025.
- Post-Advisor Benefits: Upon execution of a release, Mr. Jones is eligible for 9 months of base salary, 9 months of COBRA reimbursement, and pro-rated 2025 target bonus ($150,000 target).
- Equity Vesting: Deemed continuous service for vesting purposes until the later of 9 months post-advisor period or April 30, 2026.
- Legal Fees: Reimbursement of up to $15,000 for attorneys' fees.
Risks and Contingencies: The filing notes that Dr. Grasso's sign-on bonus is repayable if he voluntarily resigns prior to the first anniversary of the effective date. All severance payments are conditioned upon the execution of a separation agreement and release of claims.
Investor Verification Checklist
- Verify the trading status and share price of KYTX following the announcement of the new CFO.
- Review the full text of the Employment Offer Letter (Exhibit 10.1) and Jones Letter Agreement (Exhibit 10.2) for specific definitions of "Cause" and "Good Reason."
- Assess the impact of the $250,000 sign-on bonus and potential severance liabilities on the company's cash position.
- Confirm the vesting schedule and exercise price of the 450,000 stock options granted to Dr. Grasso.
- Monitor the transition period to ensure no disruption to financial reporting or accounting operations.